MannKind Corporation (MNKD)’s Run to Glory

Shares of MannKind Corporation (NASDAQ:MNKD) have nearly tripled over the last year. The value of the biotech is up a whopping 584% when you look at the company’s market cap because of all the additional shares it’s sold.

MNKD Chart

MannKind data by YCharts.

What’s caused this increase?
Increased revenue? Nope, MannKind Corporation (NASDAQ:MNKD) doesn’t have any products for sale.

Clinical trial data? Not really. The company completed enrollment for two phase 3 trials testing its inhaled insulin Afrezza in October, but the trials aren’t expected to read out until this summer.

MannKind Corporation (NASDAQ:MNKD)Big licensing deal? No, MannKind Corporation (NASDAQ:MNKD) has been talking about one for years, but nothing has materialized yet.

Instead, it looks like the price increase is simply because investors are more interested in owning MannKind than they were a year ago. More buyers and fewer sellers means the price has to go up. Valuation be damned.

Why now?
It’s the typical run-up that biotechs see before data will be released or before the Food and Drug Administration is scheduled to make a decision about a marketing application. In MannKind Corporation (NASDAQ:MNKD)’s case, it’s those phase 3 trials that are being wrapped up and should report shortly.

With no binary event in the foreseeable future — and for some traders, foreseeable can be a month, often less — few investors want to own a biotech as it’s unlikely to change in value with no news. As the binary event approaches, more people want to own the company, which drives the shares higher.

Priced in
The problem with this run up, especially for events like MannKind Corporation (NASDAQ:MNKD)’s phase 3 trials that are widely expected to be positive, is that most of the upside is already gone.

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), for instance, fell more than 20% after receiving FDA approval for its leukemia drug Iclusig. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) had more than doubled from the year before as it ran up to the decision. Shares still haven’t recovered to their pre-run-up level. Binary event traders have moved on. To add to its $3.6 billion valuation from here, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) is going to have to do it the old-fashioned way: increasing sales.

There’s risk that, even with good data, we could see the same issue for MannKind Corporation (NASDAQ:MNKD). Unless the company signs a big marketing partnership, investors are going to be rightfully worried about the launch of Afrezza after Pfizer Inc. (NYSE:PFE)‘s flop with its inhaled insulin, Exubera, a few years ago. Afrezza is arguably a much better product than Exubera, but MannKind is still going to have the same problem Pfizer Inc. (NYSE:PFE) had; invoking a paradigm shift on how doctors treat diabetics that need insulin isn’t easy and will require a lot of marketing muscle.

The article MannKind’s Run to Glory originally appeared on Fool.com and is written by Brian Orelli.

Fool contributor Brian Orelli has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Dividend Stock Alert - Billionaire Robbins' Top Dividend Idea With 70% Upside Potential

Get Paid 3.5% Per Year While Waiting For The Stock Appreciate 70%

Larry Robbins' Glenview Capital Opportunity Fund returned 101.7% in 2013 and Robbins personally made $750 million. The same fund returned 25.3% in 2014. In this FREE REPORT we will share Robbins' top dividend idea that yields 3.5% and has been increasing its dividends for 39 consecutive years. Robbins thinks the stock has the potential to appreciate 70%.

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Click here to Read Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 74 percentage points in 2.5 years. Our beta is only 1.2 (download a FREE newsletter and see the details inside)

Lists

Best Selling Magazines in the World

Shortest People in History

The Most Celebrated Holidays in the World

Most Expensive Handbag Brands in the World

Top Selling Comic Book Issues of this Century

The Most Powerful Women in Politics

Best Paid DJs

Most Rebellious Female Artists

Best Paid TV Actresses of 2014

Best Paid Actors of 2014

Most Expensive Horses in the World

Tallest People Ever

Most Encouraging Feminist Celebrities

Best Paid Supermodels of 2014

Top 10 Suburbs for Retirement in 2015

10 Wealthiest Cities in America

Top 10 TED Talks for Entrepreneurs

Best TED Talks on Education

25 Most Dangerous Places to Live in America

Top 10 Ski Resorts in the United States – 2014 List

Top 10 Most Remote Places in the World

Most Visited Museums in the United States

Wealthiest Photographers in the World

Most Famous Gay Athletes

The World’s Most Famous Circuses

Best Hair Stylists

Most Popular NASCAR Drivers

The Best Romance Movies of all Time

The Most Wanted Drug Lords

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!